ImmunomeInc Enterprise Value over EBIT from 2010 to 2024
| IMNM Stock | USD 14.27 0.39 2.66% |
Check ImmunomeInc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmunomeInc main balance sheet or income statement drivers, such as Net Interest Income of 2.9 M, Interest Income of 2.9 M or Depreciation And Amortization of 667.7 K, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0016 or PTB Ratio of 1.52. ImmunomeInc financial statements analysis is a perfect complement when working with ImmunomeInc Valuation or Volatility modules.
ImmunomeInc | Enterprise Value over EBIT |
About ImmunomeInc Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ImmunomeInc income statement, its balance sheet, and the statement of cash flows. ImmunomeInc investors use historical funamental indicators, such as ImmunomeInc's Enterprise Value over EBIT, to determine how well the company is positioned to perform in the future. Although ImmunomeInc investors may use each financial statement separately, they are all related. The changes in ImmunomeInc's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ImmunomeInc's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ImmunomeInc Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ImmunomeInc. Please read more on our technical analysis and fundamental analysis pages.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania. Immunome operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of ImmunomeInc Correlation against competitors. To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for ImmunomeInc Stock analysis
When running ImmunomeInc's price analysis, check to measure ImmunomeInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunomeInc is operating at the current time. Most of ImmunomeInc's value examination focuses on studying past and present price action to predict the probability of ImmunomeInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunomeInc's price. Additionally, you may evaluate how the addition of ImmunomeInc to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is ImmunomeInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunomeInc. If investors know ImmunomeInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunomeInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.706 | Return On Assets (0.21) | Return On Equity (1.56) |
The market value of ImmunomeInc is measured differently than its book value, which is the value of ImmunomeInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunomeInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunomeInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunomeInc's market value can be influenced by many factors that don't directly affect ImmunomeInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunomeInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunomeInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunomeInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.